A medical team in New York City says it has performed the first complete surgical transplant of a trachea. These kinds of transplants are one of the last big transplant challenges.
These structures made from living human cells are similar to human embryos at the stage when they implant in the womb. They allow scientists to research new ways to treat infertility.
Some doctors are seeing a disturbing spike in lethal alcoholic liver disease, especially among young women. The recent trend has been supercharged, they say, by the pandemic's isolation and pressures.
COVID-19 hospitalizations continue to strain U.S. hospitals. NPR built a tool to explore trends around the country. Look up your local hospital to see how it's faring.
Infusing blood plasma from people who have recovered from COVID-19 into sick patients looks good on paper. But studies of the treatment haven't found benefits.
Exposing people to a potentially fatal disease could hasten understanding of COVID-19 and development of new vaccines and treatments. But the risks of such studies raise serious ethical questions.
The Code Breaker profiles Jennifer Doudna, a Nobel Prize-winning biochemist key to the development of CRISPR, and examines the technology's exciting possibilities and need for oversight.
The third COVID-19 vaccine authorized for use in the U.S. requires one shot instead of two, and works a slightly different way from the others. Here's what we know about its safety and effectiveness.
Nonwhite Americans looking for care for a loved one are much more likely than whites to encounter discrimination, language barriers, and providers who lack cultural competence, a new report finds.
In the future, different circumstances will likely determine which vaccine or booster a person receives, based on their antibodies — and which variant is common in their region.
Researchers are trying to learn more about COVID-19 vaccines from original study participants. The quest is hampered because many people who first received a placebo shot are opting for the vaccine.